Guy W. Neff
Impact in
- Hepatology top 0.2%
- Liver Disease and Transplantation
- Hepatitis C virus research
- Liver Diseases and Immunity
- Transplantation top 0.5%
- Renal Transplantation Outcomes and Treatments
Papers in
- Hepatology 64
- Liver Disease and Transplantation 36
- Hepatitis C virus research 27
- Liver Diseases and Immunity 9
- Epidemiology 63
- Liver Disease Diagnosis and Treatment 50
- Hepatitis B Virus Studies 14
- Co-authors
- Nyingi M. Kemmer (33 shared papers)Stephen A. Harrison (16 shared papers)Eugene R. Schiff (17 shared papers)Arun Jayant Sanyal (7 shared papers)Marzia Montalbano (20 shared papers)Andreas G. Tzakis (25 shared papers)Naim Alkhouri (10 shared papers)Fred F Poordad (1 shared paper)
- Journals
- Journal of Hepatology (20 papers)Gastroenterology (11 papers)Liver Transplantation (10 papers)Transplantation (8 papers)Digestive Diseases and Sciences (8 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Guy W. Neff
147 papers receiving 8.8k citations
Guy W. Neff's Hit Papers
Peers
Comparison fields: 5 of 119
- Hepatology 3.4k
- Transplantation 465
- Epidemiology 5.1k
- Endocrinology, Diabetes and Metabolism 1.4k
- Surgery 1.8k
Countries citing papers authored by Guy W. Neff
This map shows the geographic impact of Guy W. Neff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guy W. Neff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guy W. Neff more than expected).
Fields of papers citing papers by Guy W. Neff
This network shows the impact of papers produced by Guy W. Neff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guy W. Neff. The network helps show where Guy W. Neff may publish in the future.
Co-authors
The 25 scholars most cited alongside Guy W. Neff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 151 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis Hit paper breakdown → | 2024 | 1267 |
| 2 | Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Hit paper breakdown → | 2019 | 1063 |
| 3 | Rifaximin Treatment in Hepatic Encephalopathy Hit paper breakdown → | 2010 | 997 |
| 4 | Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials Hit paper breakdown → | 2020 | 404 |
| 5 | A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis Hit paper breakdown → | 2024 | 338 |
| 6 | Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial Hit paper breakdown → | 2023 | 322 |
| 7 | Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial Hit paper breakdown → | 2021 | 296 |
| 8 | Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH Hit paper breakdown → | 2020 | 245 |
| 9 | Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis Hit paper breakdown → | 2020 | 241 |
| 10 | Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial Hit paper breakdown → | 2023 | 198 |
| 11 | 2003 | 186 | |
| 12 | 2003 | 144 | |
| 13 | The current economic burden of cirrhosis. | 2011 | 129 |
| 14 | 2004 | 109 | |
| 15 | 2002 | 101 | |
| 16 | 2004 | 99 | |
| 17 | 2004 | 96 | |
| 18 | 2021 | 96 | |
| 19 | 2012 | 93 | |
| 20 | 2022 | 86 |
About Guy W. Neff
Guy W. Neff is a scholar working on Hepatology, Epidemiology, Transplantation, Surgery and Infectious Diseases, having authored 151 papers that have together received 9.1k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (50 papers), Liver Disease and Transplantation (36 papers), Hepatitis C virus research (27 papers), Organ Transplantation Techniques and Outcomes (25 papers), Renal Transplantation Outcomes and Treatments (16 papers), Hepatitis B Virus Studies (14 papers), Liver Diseases and Immunity (9 papers) and HIV/AIDS drug development and treatment (8 papers). The work is most often cited by research in Hepatology (3.4k citations), Transplantation (465 citations), Epidemiology (5.1k citations), Endocrinology, Diabetes and Metabolism (1.4k citations) and Surgery (1.8k citations). Guy W. Neff has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Nyingi M. Kemmer, Stephen A. Harrison, Eugene R. Schiff, Arun Jayant Sanyal, Marzia Montalbano, Andreas G. Tzakis, Naim Alkhouri, Fred F Poordad, Donald J. Hillebrand and Kimberly L. Beavers. Their work appears in journals such as Journal of Hepatology, Gastroenterology, Liver Transplantation, Transplantation and Digestive Diseases and Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.